Ellagic acid, a naturally occurring plant phenol, inhibits the activity of the direct-acting mutagen N-methyl-N-nitrosourea (MeNU) in Salmonella typhimurium TA100.
mutagenicity of MeNU (0.40 mM) by 3%, 13%, 45%, and 60%, respectively. Ellagic acid (3 mM) also inhibited the mutagenic activity of NN-dimethylnitrosamine (25-200 mM) in the presence of pyrazole-induced rat liver fraction S-9. The effect of ellagic acid on DNA methylation was studied by incubating 0, 0.72, 1.32, 2.64, and 6.60 mM ellagic acid with DNA (0.9 mM nucleotide) and PHJMeNU (0.66 mM). HPLC analysis of DNA hydrolysates showed that ellagic acid caused a dose-dependent 36-84% decrease in 06-methylguanine but only a 20% decrease in the 7-methylguanine adduct. Under conditions where methylation at the 06 position of guanine in double-stranded DNA was inhibited 65% by ellagic acid, no significant inhibition of either 06-or 7-methylguanine formation was detected in single-stranded DNA. Affinity-binding studies revealed that [3H] eilagic acid binds equally to doublestranded or single-stranded DNA but that poly(dA dT) binds 1.5 times as much ellagic acid as does poly(dG-dC). The binding of ellagic acid to DNA is dependent on the concentration of both ellagic acid and DNA. The specific inhibition of 06. methylguanine formation only in double-stranded DNA and the relatively low inhibition of 7-methylguanine formation rule out the possibility that ellagic acid prevents DNA alkylation by scavenging the electrophilic intermediate generated in the hydrolysis of MeNU. The results suggest that ellagic acid inhibition of MeNU-induced mutagenicity is due to specific inhibition of methylation at the 06 position of guanine through an ellagic acid-duplex DNA afflnity-binding mechanism.
Ellagic acid (2,3,7,8-tetrahydroxy [J] benzopyrano [5,4,3-cde] [J]benzopyran-5,10-dione), a natural product shikimate derivative present in soft fruits and vegetables (1-3), inhibits the carcinogenicity of benzo[a]pyrene (B[a]P) (4) and the carcinogenicity and mutagenicity (5) (6) (7) (8) and DNA binding (9, 10) of benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE), an activated form of B[a]P. It was suggested that the chemopreventive activity of ellagic acid results from its ability to accelerate the detoxification of BPDE by forming a BPDE-ellagic acid adduct (11) . It was further suggested that the reason for the rapid reaction between BPDE and ellagic acid resulted from an initial ir-7r nonbonded interaction. The apparent second-order rate constant for the disappearance of BPDE at pH 7.0 is more than 300-fold faster in the presence of ellagic acid (11) . In summary, the proposed antimutagenic and antitumorigenic activity of ellagic acid was suggested to result from its direct interception of the "ultimate" electrophilic form of B[a]P, thereby preventing DNA adduction.
While this mechanism may be effective with the reactive electrophiles generated in the metabolism of polycyclic aromatic hydrocarbons, it is not likely that such a "scavenging" mechanism would be effective at inhibiting the activity of N-nitroso compounds. The central intermediate in the alkylation of DNA by N-nitroso compounds is a 1-alkanediazotic acid (12, 13) , which is formed directly from the hydrolysis of N-nitrosoureas, -carbamates, and -amides or indirectly from the a-oxidation of N,N-dialkylnitrosamines (Fig. 1) . The diazotic acid then ionizes to afford the corresponding alkanediazonium ion (12) (13) (14) . The transitory alkanediazonium decomposes at extremely rapid rates via a carbonium ion-type transition state (13, 14) . Accordingly, this species demonstrates little, albeit some, nucleophilic selectivity (15) (16) (17) . Thus, for a chemopreventive agent such as ellagic acid to be effective at "reasonable" concentrations against the nonselective nucleophiles generated from Nnitroso compounds, it must act with a much higher specificity than can be explained by its scavenging of electrophilic intermediates.
The data presented herein reveal that N-methyl-Nnitrosourea (MeNU)-induced mutations and in vitro DNA methylation, specifically at the 06 position of guanine, are inhibited by low concentrations of ellagic acid. The 18 -mer) were obtained from Pharmacia P-L Biochemicals.
Authentic 0t-MeGua was prepared from 2-amino-6-chloropurine (Aldrich) (18) .
Mutagenicity Studies. MeNU-induced mutations to histidine-independent growth were assessed in Salmonella Nucleic Acid Binding Assays with [3H]Ellagic Acid. ds DNA (3 mM nucleotide), ss DNA (3 mM), RNA (3 mM), (dG-dC)12.18 (15 mM) , or (dA-dT)12.18 (15 mM) was incubated overnight at 370C in a final volume of 1 ml consisting of50 mM Tris/HCl buffer (pH 7.4) with [3H]ellagic acid (7 pumol/ml, 715 mCi/mmol). At the end of incubation, the nucleic acid was precipitated and gently washed as described above. The washed and vacuum-dried nucleic acid was dissolved in 1 ml of 50 mM Tris buffer (pH 7.4), and total binding was quantitated by scintillation counting.
Ultraviolet Studies on Ellagic Acid Binding to DNA. Spectra of 3-ml incubation mixtures containing 50 mM Tris buffer (pH 7.4), 0.2-1.0 ,umol of ellagic acid, and DNA (3, 10, 15, and 20 ,umol) were monitored at 355 nm. The addition of DNA at all concentrations had no effect on the UV absorbance of ellagic acid. typhimurium strain TA100 as described by Maron and Ames (19) . Bacterial suspensions in 0.5 ml of 5 mM potassium phosphate buffer (pH 7.4) were preincubated for 10 min with dimethyl sulfoxide (20 ,ul) , or ellagic acid in dimethyl sulfoxide (20 ,ul) , at final concentrations of 0.10, 0.25, 0.50, and 1.00 mM. At the end of preincubation, 400 nmol of MeNU (final concentration 0.40 mM) was added to the incubation mixture. After 48 hr of incubation, revertants were scored on a Biotran III electronic counter (New Brunswick Scientific). All data are derived from two separate experiments performed in triplicate. The Me2NNO studies were carried out using essentially the same procedure, except liver fraction S-9 (9000 x g supernatant; ref. 19 Isolation of Alkylated DNA. At the end of the incubation period the DNA or polydeoxynucleotide was precipitated using 0.1 volume of 2.5 M sodium acetate and 2 volumes of chilled 95% ethanol. The DNA was allowed to precipitate overnight at -20°C and then centrifuged and washed repeatedly with cold 95% ethanol and acetone until the supernatant was free of radioactivity. The DNA was dried under a nitrogen-stream or in vacuo. The total binding to DNA was determined by liquid scintillation counting. DNA was quantitated either fluorimetrically (20) or by absorption at 260 nm.
Hydrolysis of Methylated DNA. MeNU-treated doublestranded (ds) or ss DNA or polydeoxynucleotide was hydrolyzed to purine bases in 0.5 ml of 0.1 M HCO for 20 hr at 37°C.
The acid hydrolysate, containing free purine bases, was neutralized by the addition of ammonium hydroxide.
Analysis of Alkylated Purine Bases. Alkylated purine bases were fractionated by HPLC essentially as described by Morimoto et al. (21) . A 100-,ul aliquot of the sample and 5 ,1 of a mixture containing authentic 7-MeGua and 06-MeGua were separated by HPLC [column, 4.6 x 250-mm Altex Ultrasphere ODS (5-,um particles); solvent, isocratic 10% methanol in 50 mM ammonium formate buffer (pH 3.5); flow rate, 1 ml/min; detection, 254 nm]. The retention times of 7-MeGua and 06-MeGua were 6.1 and 11.8 min, respectively.
The eluate was collected in 0.4-ml fractions and counted in 5 ml of Hydrocount (Baker) scintillation fluid.
RESULTS
Mutagenicity. MeNU produced a linear mutagenic dose response at concentrations of 0.05 to 0.40 mM (data not shown). The dose-dependent effect of ellagic acid on the mutagenicity of 0.40 mM MeNU is shown in Fig. 2 . Ellagic acid at nontoxic concentrations of 0.10, 0.25, 0.50, and 1.00 mM inhibited MeNU-induced mutagenicity by 3%, 13%, 45%, and 60%, respectively. Ellagic acid at the equimolar concentration of MeNU (0.40 mM) caused -34% inhibition of mutagenicity. Ellagic acid (3 mM) was very effective in preventing the mutagenic activity of Me2NNO in the presence of a pyrazole-induced S-9 activating system (Fig. 3) More detailed studies to determine the effect of ellagic acid on DNA methylation by MeNU were conducted (Table 2 ). There appears to be a threshold concentration below which ellagic acid has no effect. However, above 0.72 mM ellagic acid, a marked, dose-dependent (40% to 85%) inhibition of 06-MeGua formation was observed, while only a 20% decrease in the 7-MeGua adduct was seen at all ellagic acid concentrations tested above 0.72 mM. The inhibitory effect of ellagic acid was also observed with (dGdC)12_18 (Table 3) .
Consistent with a noncovalent binding hypothesis, no inhibition was observed in the MeNU-mediated methylation of ss DNA (Table 3) .
Binding of Eliagic Acid to DNA. Attempts to perform competitive binding studies using equilibrium dialysis were unsuccessful because ellagic acid bound to the dialysis tubing. A series of experiments was then conducted to address the noncompetitive affinity binding of ellagic acid to DNA and to determine whether there was any preference for G*C versus A-T base pair sequences or ss versus ds DNA. Table 4 shows the noncompetitive binding of [3H]ellagic acid with various DNAs, including ds DNA, poly(dG-dC) and poly(dA dT), and ss DNA. There was no significant difference in binding between ds and ss DNA. Poly(dA-dT) bound 1.5-fold more ellagic acid than did poly(dG-dC), indicating that ellagic acid should have a preference for A+T-rich sites in DNA. UV studies on the interaction of ellagic acid with DNA showed no change in absorbance or UV maximum of ellagic acid at 355 nm with increasing concentrations of DNA (results not shown). It should be pointed out that the [3H]ellagic acid used in the above affinity-binding studies contained -5% radioactive impurity. However, UV quantitation of DNA affinity binding with pure nonlabeled ellagic acid showed the same results, but the studies could only be carried out at the higher concentrations of ellagic acid because of the lower sensitivity of the method. DISCUSSION N-Nitroso compounds (N,N-dialkylnitrosamines, N-alkyl-N-nitrosoureas, etc.) comprise a class of carcinogens possibly involved in the etiology of human cancer. It has been suggested that mutagenicity and carcinogenicity of N-nitroso Each value is the mean of three replicate determinations. (b) Binding was assayed as in a, except that ellagic acid concentration was 6.6 mM and DNA concentration was varied. Each value is the mean of three determinations.
compounds are related to their ability to alkylate DNA (22, 23) . Since the initial study by Loveless (24) , several lines of evidence indicate that 06-alkylguanine is one of the critical lesions in DNA that is associated with mutagenesis and carcinogenesis by N-nitroso compounds (25) (26) (27) (28) (29) (30) .
The present study demonstrates that ellagic acid at low and nontoxic concentrations (i) inhibits the mutagenicity of MeNU and Me2NNO, (it) inhibits the MeNU-mediated methylation of guanine in DNA at the 06 position without significantly altering methylation at the N-7 position, and (iii) inhibits the MeNU-mediated methylation ofguanine at the 06 position only when ds DNAs are used as substrate. These results indicate the involvement of a very different mechanism than that proposed for the ellagic acid-mediated prevention of BPDE mutagenicity and carcinogenicity (11) . In the BPDE work, data were presented that are consistent with an efficient scavenging of electrophilic BPDE by ellagic acid.
Our data indicate a mechanism dependent on ellagic acid-duplex DNA binding being responsible for the prevention of MeNU-mediated mutagenicity and DNA methylation. It has previously been shown that spermidine, which binds to A-T sites in DNA, can inhibit methylation of rat liver chromatin in a dose-dependent way (31) . In those studies MeNU was the methylating agent and 90%o inhibition occurred with 0.10 mM spermidine and 2.0 mM MeNU in the presence of 0.6 mM (nucleotide) chromatin or DNA. Under the same conditions, 0.0125 mM spermidine gave 25% inhibition of methylation. In the same incubation mixture the methylation of 2'-deoxy-5'-guanylic acid was not affected by spermidine. The interpretation of these data was that the spermidine inhibition is specific for duplex DNA because of its unique structure. Distamycin A, a DNA minor-groove binder that has an affinity for A+T-rich sites (32) , also inhibited guanine methylation in a dose-dependent manner (31) . This (34) , and it does show some preference for A+T-rich sequences.
The specific blocking of 06 guanine methylation by ellagic acid is the first report to our knowledge in which an inhibitor has been shown to diminish specifically the formation of an 06-alkylguanine adduct. Our data at this time are limited to events occurring at the 06 and N-7 positions of guanine. Both of these sites face into the major groove. However, the minor-groove binders distamycin and spermidine also inhibit methylation at these two major groove sites (31) . It is possible that ellagic acid may indirectly inhibit the methylation reaction by altering the conformation of DNA near its binding site(s) so as to make the major groove 06 atom less accessible to the methylating species. Another possibility is that when ellagic acid binds to DNA, it is positioned in such a way as to efficiently scavenge reactive intermediate that approaches the 06 position of guanine. We do not know how ellagic acid-DNA binding might affect methylation at other nucleophilic positions in DNA.
Based on the proposed mechanism of action, ellagic acid should be effective at preventing the mutagenicity of N,Ndialkylnitrosamines. In fact, we have found that ellagic acid almost completely inhibits the mutagenicity of Me2NNO in S. typhimurium TA100 in the presence of pyrazole-induced rat liver S-9 (Fig. 4) . This inhibition was observed at Me2NNO concentrations ranging from 25 to 200 mM with 3 mM ellagic acid. In the absence of ellagic acid, a linear mutagenic dose response to Me2NNO was observed, with approximately 1100 revertants scored at the highest Me2NNO concentration. Ellagic acid had no effect on Me2NNO metabolism as measured by formaldehyde production (data not shown).
The results of the present study, which indicate the potential use of ellagic acid as a clinical chemopreventive agent and as a mechanistic tool to probe the biological significance of specific DNA adducts, clearly justify continued research on ellagic acid.
We 
